LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 92

Search options

  1. Article ; Online: Antimicrobial Strategies for Cystic Fibrosis.

    Møller, Rikke / Pressler, Tacjana / Qvist, Tavs

    Seminars in respiratory and critical care medicine

    2022  Volume 44, Issue 2, Page(s) 297–306

    Abstract: Lung infection is the leading cause of death in cystic fibrosis (CF), and antimicrobial therapies are the backbone of infection management. While many different strategies may be applied, rigorous microbiological surveillance, intensive eradication ... ...

    Abstract Lung infection is the leading cause of death in cystic fibrosis (CF), and antimicrobial therapies are the backbone of infection management. While many different strategies may be applied, rigorous microbiological surveillance, intensive eradication therapy, and long-term maintenance therapy based on inhaled antibiotics may be considered the main strategy for infection control in individuals with CF. While most of the existing evidence is based on infection with
    MeSH term(s) Humans ; Cystic Fibrosis/complications ; Cystic Fibrosis/drug therapy ; Cystic Fibrosis/microbiology ; Pseudomonas Infections/drug therapy ; Anti-Bacterial Agents/therapeutic use ; Administration, Inhalation ; Pseudomonas aeruginosa
    Chemical Substances Anti-Bacterial Agents
    Language English
    Publishing date 2022-12-19
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1183617-9
    ISSN 1098-9048 ; 1069-3424
    ISSN (online) 1098-9048
    ISSN 1069-3424
    DOI 10.1055/s-0042-1758733
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1555: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Book ; Thesis: IgG subclasses and chronic bacterial infection

    Pressler, Tacjana

    subclass antibodies and the clinical course of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis

    (Acta pathologica, microbiologica et immunologica Scandinavica : Supplementum ; 66)

    1996  

    Author's details by Tacjana Pressler
    Series title Acta pathologica, microbiologica et immunologica Scandinavica : Supplementum ; 66
    Acta pathologica, microbiologica et immunologica Scandinavica
    Acta pathologica, microbiologica et immunologica Scandinavica ; Supplementum
    Collection Acta pathologica, microbiologica et immunologica Scandinavica
    Acta pathologica, microbiologica et immunologica Scandinavica ; Supplementum
    Keywords Pseudomonas aeruginosa / immunology ; Pseudomonas Infections / immunology ; Antibodies, Bacterial ; Cystic Fibrosis / complications
    Language English
    Size 41 S. : Ill., graph. Darst.
    Publisher Munksgaard
    Publishing place Copenhagen
    Publishing country Denmark
    Document type Book ; Thesis
    Thesis / German Habilitation thesis København, Univ., Diss., 1996
    HBZ-ID HT007396595
    ISBN 87-16-15649-8 ; 978-87-16-15649-5
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Ud II Zs 73 -Suppl.66- verfügbar in Königswinter Königswinter

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Antimicrobial Strategies for Cystic Fibrosis

    Møller, Rikke / Pressler, Tacjana / Qvist, Tavs

    Seminars in Respiratory and Critical Care Medicine

    (Cystic Fibrosis)

    2022  Volume 44, Issue 02, Page(s) 297–306

    Abstract: Lung infection is the leading cause of death in cystic fibrosis (CF), and antimicrobial therapies are the backbone of infection management. While many different strategies may be applied, rigorous microbiological surveillance, intensive eradication ... ...

    Series title Cystic Fibrosis
    Abstract Lung infection is the leading cause of death in cystic fibrosis (CF), and antimicrobial therapies are the backbone of infection management. While many different strategies may be applied, rigorous microbiological surveillance, intensive eradication therapy, and long-term maintenance therapy based on inhaled antibiotics may be considered the main strategy for infection control in individuals with CF. While most of the existing evidence is based on infection with Pseudomonas aeruginosa, other important pathogens causing lung inflammation and deterioration exist and should be treated despite the evidence gap. In this chapter, we describe the approaches to the antimicrobial treatment of the most important pathogens in CF and the evidence behind.
    Keywords nontuberculous mycobacteria ; evidence ; eradication ; inhaled antibiotics
    Language English
    Publishing date 2022-12-19
    Publisher Thieme Medical Publishers, Inc.
    Publishing place Stuttgart ; New York
    Document type Article
    ZDB-ID 1183617-9
    ISSN 1098-9048 ; 1069-3424
    ISSN (online) 1098-9048
    ISSN 1069-3424
    DOI 10.1055/s-0042-1758733
    Database Thieme publisher's database

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1555: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Changes in glucose tolerance in people with cystic fibrosis after initiation of first-generation CFTR modulator treatment.

    Ekblond, Rikke Spragge / Nielsen, Bibi Uhre / Højte, Christine / Almdal, Thomas Peter / Shaw, James / Pressler, Tacjana / Faurholt-Jepsen, Daniel / Mathiesen, Inger Hee Mabuza

    Pediatric pulmonology

    2023  Volume 58, Issue 9, Page(s) 2600–2609

    Abstract: Background: Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have been shown to have a beneficial effect on pulmonary function and nutritional status in patients with cystic fibrosis (CF), but the extent to which they affect glucose ...

    Abstract Background: Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have been shown to have a beneficial effect on pulmonary function and nutritional status in patients with cystic fibrosis (CF), but the extent to which they affect glucose tolerance is not fully understood. In the current study, we evaluated the change in glucose tolerance and insulin secretion after first-generation CFTR modulator treatment in adults with CF.
    Methods: We performed a longitudinal observational study with an oral glucose tolerance test performed at baseline and after three and a half years of follow-up. The test comprised glucose, C-peptide and insulin measured at fasting, 1 h, and 2 h, and HbA1c at fasting. We compared changes in parameters of glucose tolerance and insulin secretion from baseline to follow-up.
    Results: Among 55 participants, 37 (67%) were treated with a first-generation CFTR modulator for a median of 21 months. Glucose levels were unchanged in both the treated and untreated group. In the treated group, C-peptide levels declined, yet no significant differences in glucose, insulin, and C-peptide levels were observed between the groups. HbA1c increased in both groups, while no significant change in the insulin sensitivity indices was detected in either group. However, homeostatic model assessment for insulin resistance tended to decline in the treated group, whilst tending towards an increase in the untreated group. The difference between the groups reached statistical significance (p = 0.040).
    Conclusion: Treatment with first-generation CFTR modulators, mainly tezacaftor/ivacaftor, did not seem to be associated with glucose tolerance nor insulin secretion in adults with CF. However, CFTR modulators may still have a beneficial effect on insulin sensitivity.
    MeSH term(s) Adult ; Humans ; Cystic Fibrosis/drug therapy ; Cystic Fibrosis Transmembrane Conductance Regulator/genetics ; Insulin Resistance ; C-Peptide ; Glycated Hemoglobin ; Insulin ; Glucose ; Aminophenols/therapeutic use ; Benzodioxoles ; Mutation
    Chemical Substances Cystic Fibrosis Transmembrane Conductance Regulator (126880-72-6) ; C-Peptide ; Glycated Hemoglobin ; Insulin ; Glucose (IY9XDZ35W2) ; Aminophenols ; Benzodioxoles ; CFTR protein, human
    Language English
    Publishing date 2023-06-21
    Publishing country United States
    Document type Observational Study ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 632784-9
    ISSN 1099-0496 ; 8755-6863
    ISSN (online) 1099-0496
    ISSN 8755-6863
    DOI 10.1002/ppul.26562
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2143: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Antimicrobial resistance of Pseudomonas aeruginosa in a cystic fibrosis population after introduction of a novel cephalosporin/β-lactamase inhibitor combination.

    Katzenstein, Terese L / Faurholt-Jepsen, Daniel / Qvist, Tavs / Jensen, Peter Østrup / Pressler, Tacjana / Johansen, Helle Krogh / Kolpen, Mette

    APMIS : acta pathologica, microbiologica, et immunologica Scandinavica

    2023  Volume 131, Issue 8, Page(s) 419–425

    Abstract: Ceftolozane-tazobactam is a new β-lactam/β-lactamase inhibitor combination approved by the U.S. Food and Drug Administration in 2019 for the treatment of hospital-acquired and ventilator-associated pneumonia. The combination is a particularly potent ... ...

    Abstract Ceftolozane-tazobactam is a new β-lactam/β-lactamase inhibitor combination approved by the U.S. Food and Drug Administration in 2019 for the treatment of hospital-acquired and ventilator-associated pneumonia. The combination is a particularly potent inhibitor of penicillin-binding proteins with higher affinity than other β-lactam agents. Persons with cystic fibrosis (pwCF) often harbour resistant Gram-negative bacteria in the airways and need antibiotics to prevent declining lung function. To test whether the introduction of ceftolozane-tazobactam in the period 2015-2020 led to a bacterial population level increase in cephalosporin resistance in a Danish CF population. In vitro, activity of ceftolozane-tazobactam was evaluated by susceptibility testing of clinical Pseudomonas aeruginosa isolated from pwCF from January 1, 2015, to June 1, 2020. Six thousand three hundred thirty two isolates collected from 210 adult pwCF were included. Thirty pwCF were treated with ceftolozane-tazobactam at least once. Ceftolozane-tazobactam exposure did not increase cephalosporin resistance on an individual or population level. However, resistance to ceftolozane-tazobactam was recorded despite no prior exposure in four pwCF. Compared to ceftazidime, ceftolozane-tazobactam had a better in vitro activity on P. aeruginosa. The percentage of non-mucoid P. aeruginosa isolates susceptible to ceftolozane-tazobactam were higher or equal to 5 other β-lactams. Ceftolozane-tazobactam expands the armamentaria against P. aeruginosa with acceptable levels for a selection of drug resistance.
    MeSH term(s) Humans ; Adult ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; beta-Lactamase Inhibitors/pharmacology ; beta-Lactamase Inhibitors/therapeutic use ; Pseudomonas aeruginosa ; Cystic Fibrosis/microbiology ; Cephalosporinase/pharmacology ; Cephalosporinase/therapeutic use ; Drug Resistance, Bacterial ; Cephalosporins/pharmacology ; Cephalosporins/therapeutic use ; Tazobactam/pharmacology ; Tazobactam/therapeutic use ; Monobactams/pharmacology ; Monobactams/therapeutic use ; Microbial Sensitivity Tests ; Pseudomonas Infections/drug therapy ; Pseudomonas Infections/microbiology ; Drug Resistance, Multiple, Bacterial
    Chemical Substances ceftolozane (37A4IES95Q) ; Anti-Bacterial Agents ; beta-Lactamase Inhibitors ; Cephalosporinase (EC 3.5.2.-) ; Cephalosporins ; ceftolozane, tazobactam drug combination ; Tazobactam (SE10G96M8W) ; Monobactams
    Language English
    Publishing date 2023-06-09
    Publishing country Denmark
    Document type Journal Article
    ZDB-ID 93340-5
    ISSN 1600-0463 ; 0903-4641
    ISSN (online) 1600-0463
    ISSN 0903-4641
    DOI 10.1111/apm.13331
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ud II Zs.73: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Targeting airway inflammation in cystic fibrosis in children: past, present, and future.

    Pressler, Tacjana

    Paediatric drugs

    2011  Volume 13, Issue 3, Page(s) 141–147

    Abstract: Inflammation is a major component of the vicious cycle characterizing cystic fibrosis (CF) pulmonary disease. If untreated, this inflammatory process irreversibly damages the airways, leading to bronchiectasis and ultimately respiratory failure. Anti- ... ...

    Abstract Inflammation is a major component of the vicious cycle characterizing cystic fibrosis (CF) pulmonary disease. If untreated, this inflammatory process irreversibly damages the airways, leading to bronchiectasis and ultimately respiratory failure. Anti-inflammatory drugs for CF lung disease appear to have beneficial effects on disease progression. These agents include oral corticosteroids and ibuprofen, as well as azithromycin, which, in addition to its antimicrobial effects, also possess anti-inflammatory properties. Inhaled corticosteroids, antioxidants, nutritional supplements, and protease inhibitors have a limited impact on the disease. Adverse effects limit therapy with oral corticosteroids and ibuprofen. Azithromycin appears to be safe and effective, and is thus the most promising anti-inflammatory therapy available for patients with CF. Pharmacologic therapy with anti-inflammatory agents should be started early in the disease course, before extensive irreversible lung damage has occurred. To optimize anti-inflammatory therapy, it is necessary to understand the mechanism of action of these agents in the CF lung, to determine which of these agents would provide the most benefit to patients with CF, and to determine which therapies should be initiated at what age or stage of lung disease.
    MeSH term(s) Animals ; Cystic Fibrosis/complications ; Drug Delivery Systems/methods ; Drug Delivery Systems/trends ; Humans ; Inflammation/complications ; Inflammation/drug therapy ; Respiratory System/drug effects
    Language English
    Publishing date 2011-05-03
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 1492748-2
    ISSN 1179-2019 ; 1174-5878
    ISSN (online) 1179-2019
    ISSN 1174-5878
    DOI 10.2165/11588150-000000000-00000
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5205: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: The choice of lung function reference equation affects clinical trial eligibility: Results from a cystic fibrosis cohort.

    Mathiesen, Inger Hee / Ronit, Andreas / Pressler, Tacjana

    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

    2018  Volume 17, Issue 5, Page(s) e46–e47

    MeSH term(s) Adolescent ; Adult ; Aged ; Clinical Trials as Topic ; Cohort Studies ; Cystic Fibrosis/physiopathology ; Female ; Humans ; Male ; Middle Aged ; Patient Selection ; Reference Standards ; Scandinavian and Nordic Countries ; Spirometry/standards
    Language English
    Publishing date 2018-06-20
    Publishing country Netherlands
    Document type Letter ; Multicenter Study
    ZDB-ID 2091075-7
    ISSN 1873-5010 ; 1569-1993
    ISSN (online) 1873-5010
    ISSN 1569-1993
    DOI 10.1016/j.jcf.2018.05.017
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Cystic fibrosis - an example of personalized and precision medicine.

    Skov, Marianne / Hansen, Christine Rønne / Pressler, Tacjana

    APMIS : acta pathologica, microbiologica, et immunologica Scandinavica

    2019  Volume 127, Issue 5, Page(s) 352–360

    Abstract: Cystic fibrosis (CF) is a severe, monogenic, autosomal recessive disease caused by mutations in the CFTR (cystic fibrosis transmembrane regulator) gene, where disturbed chloride and bicarbonate transportation in epithelial cells results in a multiorgan ... ...

    Abstract Cystic fibrosis (CF) is a severe, monogenic, autosomal recessive disease caused by mutations in the CFTR (cystic fibrosis transmembrane regulator) gene, where disturbed chloride and bicarbonate transportation in epithelial cells results in a multiorgan disease with primarily pulmonary infections and pancreatic insufficiency. In 1968, the Copenhagen CF Center was established, and centralized care of CF patients with monthly control was introduced. Close monitoring and treatment of Pseudomonas lung infection as well as segregation of patients with different infection status improved the clinical outcome as well as survival. Prophylactic basic treatment as well as infection treatments follow specific algorithms. A variety of comorbidities have all along the pulmonary infection control necessitated personalized care, adjusted to the patients' phenotype. With the introduction of CFTR modulators, the treatment has shifted from prophylactic, symptomatic type toward a new era of precision medicine targeting the basic defect according to the patients' CFTR genotype. Future directions will focus on further improvement of the CFTR modulators and gene therapy, as well as modifier genes and CF phenotype.
    MeSH term(s) Centralized Hospital Services ; Comorbidity ; Cystic Fibrosis/microbiology ; Cystic Fibrosis/mortality ; Cystic Fibrosis/therapy ; Cystic Fibrosis Transmembrane Conductance Regulator/genetics ; Genetic Therapy ; Humans ; Lung/microbiology ; Precision Medicine ; Pseudomonas aeruginosa/isolation & purification
    Chemical Substances Cystic Fibrosis Transmembrane Conductance Regulator (126880-72-6)
    Language English
    Publishing date 2019-02-14
    Publishing country Denmark
    Document type Journal Article ; Review
    ZDB-ID 93340-5
    ISSN 1600-0463 ; 0903-4641
    ISSN (online) 1600-0463
    ISSN 0903-4641
    DOI 10.1111/apm.12915
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ud II Zs.73: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Transmission and Antibiotic Resistance of

    Gabrielaite, Migle / Bartell, Jennifer A / Nørskov-Lauritsen, Niels / Pressler, Tacjana / Nielsen, Finn C / Johansen, Helle K / Marvig, Rasmus L

    Journal of clinical microbiology

    2021  Volume 59, Issue 4

    Abstract: ... ...

    Abstract Achromobacter
    MeSH term(s) Achromobacter/genetics ; Cystic Fibrosis/complications ; Drug Resistance, Microbial ; Gram-Negative Bacterial Infections/epidemiology ; Humans ; Phylogeny
    Language English
    Publishing date 2021-03-19
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 390499-4
    ISSN 1098-660X ; 0095-1137
    ISSN (online) 1098-660X
    ISSN 0095-1137
    DOI 10.1128/JCM.02911-20
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1188: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Omics-based tracking of

    Bartell, Jennifer A / Sommer, Lea M / Marvig, Rasmus L / Skov, Marianne / Pressler, Tacjana / Molin, Søren / Johansen, Helle Krogh

    The European respiratory journal

    2021  Volume 57, Issue 4

    Abstract: ... ...

    Abstract Whenever
    MeSH term(s) Anti-Bacterial Agents/therapeutic use ; Cystic Fibrosis/drug therapy ; Humans ; Phylogeny ; Pseudomonas Infections/drug therapy ; Pseudomonas aeruginosa/genetics
    Chemical Substances Anti-Bacterial Agents
    Language English
    Publishing date 2021-04-08
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 639359-7
    ISSN 1399-3003 ; 0903-1936
    ISSN (online) 1399-3003
    ISSN 0903-1936
    DOI 10.1183/13993003.00512-2020
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2322: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 292: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top